FDA clears trial of Ampio's knee osteoarthritis drug

04/5/2013 | BeckersASC.com

Ampio Pharmaceuticals obtained FDA approval to initiate a clinical trial of Ampion, a non-steroidal anti-inflammatory biologic drug, in patients with knee osteoarthritis. Ampio is eligible to submit a biologics license application once the trial ends.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA